ArticleImmunity2020
Mutant KRAS at the Heart of Tumor Immune Evasion.
Article in Immunity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Systematic and precise interventions for KRAS-mutant cancers.Experimental hematology & oncology · 2026Review
- KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of Immunotherapy.Cancers · 2025Review
- Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy.Cancer metastasis reviews · 2025Review
- Pancreatic Ductal Adenocarcinoma with Medullary Features and a Complete Pathological Response After Neoadjuvant FOLFIRINOX: A Case Report and Literature Review.Journal of gastrointestinal cancer · 2025Review
- A novel intranasal peptide vaccine inhibits non-small cell lung cancer with KRAS mutation.Cancer gene therapy · 2024Article
- Mutant KRAS-activated circATXN7 fosters tumor immunoescape by sensitizing tumor-specific T cells to activation-induced cell death.Nature communications · 2024Article
- Leveraging a KRAS-based signature to predict the prognosis and drug sensitivity of colon cancer and identifying SPINK4 as a new biomarker.Scientific reports · 2023Article
- Transformation of immunosuppressive mtKRAS tumors into immunostimulatory tumors by Nerofe and Doxorubicin.Oncotarget · 2023Article
- Patient-Derived Tumoroid for the Prediction of Radiotherapy and Chemotherapy Responses in Non-Small-Cell Lung Cancer.Biomedicines · 2023Article
- Covalent inhibitor targets KRasGenes & diseases · 2023Review
- Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer.Frontiers in oncology · 2023Review
- AZD4625 is a Potent and Selective Inhibitor of KRASG12C.Molecular cancer therapeutics · 2022Article
- Daily Practice Assessment ofCancers · 2022Review
- Immune Subtypes in LUAD Identify Novel Tumor Microenvironment Profiles With Prognostic and Therapeutic Implications.Frontiers in immunology · 2022Article
- KRAS mutation: from undruggable to druggable in cancer.Signal transduction and targeted therapy · 2021Review
- Implementation of CRISPR/Cas9 Genome Editing to Generate Murine Lung Cancer Models That Depict the Mutational Landscape of Human Disease.Frontiers in cell and developmental biology · 2021Article
- TargetingJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Article
- Inhibition of RAS: proven and potential vulnerabilities.Biochemical Society transactions · 2020Review
- Overcoming Resistance to Drugs TargetingInnovation (Cambridge (Mass.)) · 2020Article
- Biology, pathology, and therapeutic targeting of RAS.Advances in cancer research · 2020Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the search for therapeutic combinations for the treatment of cancer, the pairing of targeted inhibitors of oncogenic driver pathways with immunotherapy has largely been overlooked. In Nature, Canon et al. (2019) describe how the novel KRAS-G12C inhibitor AMG 510 can potentiate immune rejection in combination with immune checkpoint blockade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.